Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nooshin, Tavoosi"'
Autor:
Saeid, Roozpeykar, Maryam, Azizian, Zohreh, Zamani, Marjan Rahimi, Farzan, Hossein Abdollahi, Veshnavei, Nooshin, Tavoosi, Arash, Toghyani, Amirhossein, Sadeghian, Mahdieh, Afzali
Publikováno v:
Am J Nucl Med Mol Imaging
Magnetic resonance imaging (MRI) is widely used in meningeal lesions due to rapid and accurate diagnosis and prevention of serious complications. The aim of the present study was to compare these two sequences after injection of a contrast agent into
Autor:
Maryam, Azizian, Nadia, Ghasemi Darestani, Athena, Aliabadi, Mahdieh, Afzali, Nooshin, Tavoosi, Mahnaz, Fosouli, Jalil, Khataei, Halimeh, Aali, Sayed Mohammad Amin, Nourian
Publikováno v:
Am J Neurodegener Dis
Background: Multiple Sclerosis (MS) is an autoimmune, inflammatory disease of the central nervous system. Magnetic resonance imaging (MRI) findings are associated with disease clinical activity and response to treatment. This study aimed to evaluate
Autor:
Mina, Shakery Boroujeni, Maryam, Azizian, Mahshid, Bahrami, Azin, Kheradmand, Nooshin, Tavoosi, Zeynab, Rostamiyan, Khatereh, Forouharnejad, Sarina, Ahmadian, Iman, Naamipouran, Mehdi, Kiaei
Publikováno v:
Int J Physiol Pathophysiol Pharmacol
Background: COVID-19 infection is a severe condition in pregnant women. Previous studies have suggested that anti-COVID-19 antibodies may be able to be transmitted from mother to fetus, which in itself is a protective factor in infants against the di
Publikováno v:
Int J Physiol Pathophysiol Pharmacol
Objectives: The complications of normal vaginal delivery (NVD) are one of the issues that researchers have been discussing today and various ways to reduce these outcomes have been presented. In this study, we aimed to compare the effect of Transcuta
Autor:
Ali, Momeni, Rana, Abrishamkar, Fatemeh, Panahi, Sepehr, Eslami, Nooshin, Tavoosi, Aryan, Rafiee Zadeh
Publikováno v:
American journal of clinical and experimental immunology. 8(4)
Fingolimod is the first oral drug approved by Food and Drug Administration (FDA) of United States for treating patients with relapsing-remitting multiple sclerosis (RRMS). Fingolimod acts by immunomodulation but there are still much remained about it